Literature DB >> 8894198

Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.

J Zohar1, R Judge.   

Abstract

BACKGROUND: The aim was to assess the effect of a flexible dose of paroxetine, compared with clomipramine and placebo, in obsessive-compulsive disorder (OCD).
METHOD: In a multinational randomised study, 406 subjects with OCD of at least six months duration received double-blind medication for up to 12 weeks. Doses were adjusted according to therapeutic effect and side-effects. Primary efficacy measures were the Yale-Brown Obsessive-Compulsive Scale and the National Institute of Mental Health Obsessive-Compulsive Scale. Secondary efficacy measures were the Montgomery-Asberg Depression Rating Scale, Symptom Check-List (90), Clinical Global Impression, and Patients Global Evaluation.
RESULTS: Paroxetine was significantly more effective than placebo, and of comparable efficacy to clomipramine. Paroxetine had significantly superior tolerability to clomipramine on three measures: CGI efficacy index, anticholinergic adverse events, and adverse events leading to withdrawal.
CONCLUSION: Paroxetine is as effective as clomipramine in the treatment of OCD. The comparable efficacy and better tolerability of paroxetine suggest that it would be an appropriate treatment for OCD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894198     DOI: 10.1192/bjp.169.4.468

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  29 in total

1.  Prefrontal serotonin depletion affects reversal learning but not attentional set shifting.

Authors:  H F Clarke; S C Walker; H S Crofts; J W Dalley; T W Robbins; A C Roberts
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

Review 2.  Obsessive-compulsive disorder.

Authors:  I Heyman; D Mataix-Cols; N A Fineberg
Journal:  BMJ       Date:  2006-08-26

3.  Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder.

Authors:  A Heiden; M de Zwaan; R Frey; O Presslich; S Kasper
Journal:  J Psychiatry Neurosci       Date:  1998-05       Impact factor: 6.186

Review 4.  Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.

Authors:  N S Gunasekara; S Noble; P Benfield
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 5.  Diagnosis and treatment of pathologic gambling.

Authors:  Erica D Sood; Stefano Pallanti; Eric Hollander
Journal:  Curr Psychiatry Rep       Date:  2003-05       Impact factor: 5.285

6.  Paroxetine for somatic pain associated with physical illness: a review.

Authors:  Prakash S Masand; Meera Narasimhan; Ashwin A Patkar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

Review 7.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 8.  Antiepileptic drugs in the treatment of anxiety disorders: role in therapy.

Authors:  Michael Van Ameringen; Catherine Mancini; Beth Pipe; Mark Bennett
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; S Patricia Chou; Risë B Goldstein; Boji Huang; Frederick S Stinson; Tulshi D Saha; Sharon M Smith; Deborah A Dawson; Attila J Pulay; Roger P Pickering; W June Ruan
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.